Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea

키워드

참고문헌 (152)

1. 이동건, "조혈모세포이식 환자에서 흔히 보는 감염", 대한내과학회지, 84(2), pp.158~167 (2013), 대한내과학회[DOI]
2. Wingard JR, "Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology", Hematol Oncol Clin North Am, 25, pp.101~116 (2011)[DOI]
3. Tomblyn M, "Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective", Biol Blood Marrow Transplant, 15, pp.1143~1238 (2009)[DOI]
4. Safdar A, "Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects", Clin Infect Dis, 53, pp.798~806 (2011)[DOI]
5. Lee JW, "The activity of hematopoietic stem cell transplantation in Korea", Bone Marrow Transplant, 42(Suppl 1), pp.S92~S95 (2008)[DOI]
6. Yoo JH, "Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea", Bone Marrow Transplant, 34, pp.497~504 (2004)[DOI]
7. 박선희, "Current Trends of Infectious Complications following Hematopoietic Stem Cell Transplantation in a Single Center", Journal of Korean Medical Science, 21(2), pp.199~207 (2006), 대한의학회
8. Kim SH, "Infectious complications following allogeneic stem cell transplantation: reduced- intensity vs. myeloablative conditioning regimens", Transpl Infect Dis, 15, pp.49~59 (2013)[DOI]
9. Bosch M, "Immune reconstitution after hematopoietic cell transplantation", Curr Opin Hematol, 19, pp.324~335 (2012)[DOI]
10. Seggewiss R, "Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update", Blood, 115, pp.3861~3868 (2010)[DOI]
11. Ogonek J, "Immune reconstitution after allogeneic hematopoietic stem cell transplantation", Front Immunol, 7, pp.507~ (2016)
12. Dropulic LK, "Overview of infections in the immunocompromised host;Diagnostic Microbiology of the Immunocompromised Host, 1st ed", pp.3~43 (2009), ASM Press
13. 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
14. Sahin U, "An overview of infectious complications after allogeneic hematopoietic stem cell transplantation", J Infect Chemother, 22, pp.505~514 (2016)[DOI]
15. Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America", Clin Infect Dis, 52, pp.e56~e93 (2011)[DOI]
16. EORTC International Antimicrobial Therapy Cooperative Group, "Gram-positive bacteraemia in granulocytopenic cancer patients", Eur J Cancer, 26, pp.569~574 (1990)[DOI]
17. Klastersky J, "Science and pragmatism in the treatment and prevention of neutropenic infection", J Antimicrob Chemother, 41(Suppl D), pp.13~24 (1998)
18. Mikulska M, "Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients", J Infect, 68, pp.321~331 (2014)[DOI]
19. Jun HX, "Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever", Int J Antimicrob Agents, 26(Suppl 2), pp.S128~S132 (2005)[DOI]
20. 최수미, "급성 백혈병 환자의 감염양상 : 관해 유도 및 재관해유도 화학요법 환자군의 비교", Infection and Chemotherapy, 35(2), pp.78~85 (2003), 대한감염학회
21. Kim HB, "Infections in patients with acute leukemia (1993-1996)", Korean J Hematol, 34, pp.359~365 (1999)
22. 권재철, "Epidemiology and Clinical Features of Bloodstream Infections in Hematology Wards: One Year Experience at the Catholic Blood and Marrow Transplantation Center", Infection and Chemotherapy, 45(1), pp.51~61 (2013), 대한감염학회[DOI]
23. Hammarstrom V, "Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients", Transplantation, 69, pp.1582~1586 (2000)
24. Gustinetti G, "Bloodstream infections in neutropenic cancer patients: a practical update", Virulence, 7, pp.280~297 (2016)[DOI]
25. Gudiol C, "Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients", Clin Microbiol Infect, 19, pp.474~479 (2013)[DOI]
26. Kim SH, "Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum <TEX>${\beta}$<", TEX>-lactamase production and its impact on outcome, 2013, pp.92, 533~541
27. Prabhash K, "Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern", Indian J Cancer, 47, pp.184~188 (2010)[DOI]
28. Girmenia C, "Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy", Bone Marrow Transplant, 50, pp.282~288 (2015)[DOI]
29. Gedik H, "Bloodstream infections in patients with hematological malignancies: which is more fatal. Cancer or resistant pathogens?", Ther Clin Risk Manag, 10, pp.743~752 (2014)
30. Giannella M, "Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study", Clin Microbiol Infect, 20, pp.1357~1362 (2014)[DOI]
31. Kim SB, "Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients", Scand J Infect Dis, 46, pp.81~88 (2014)[DOI]
32. Cho SY, "Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study", BMC Infect Dis, 13, pp.504~ (2013)[DOI]
33. Bow EJ, "Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients", Curr Opin Infect Dis, 24, pp.545~553 (2011)[DOI]
34. Cullen M, "Prevention of febrile neutropenia: use of prophylactic antibiotics", Br J Cancer, 101(Suppl 1), pp.S11~S14 (2009)[DOI]
35. Neumann S, "Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)", Ann Hematol, 92, pp.433~442 (2013)[DOI]
36. Kanafani ZA, "Epidemiology and risk factors for extended-spectrum beta- lactamase-producing organisms: a case control study at a tertiary care center in Lebanon", Am J Infect Control, 33, pp.326~332 (2005)[DOI]
37. Lautenbach E, "Extended-spectrum beta-lactamase-producing Escherichia coli and Pseudomonas aeruginosa: risk factors for infection and impact of resistance on outcomes", Clin Infect Dis, 32, pp.1162~1171 (2001)[DOI]
38. Colodner R, "Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients", Eur J Clin Microbiol Infect Dis, 23, pp.163~167 (2004)[DOI]
39. Craig M, "The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit", Bone Marrow Transplant, 39, pp.477~482 (2007)[DOI]
40. Cumpston A, "Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit", Transpl Infect Dis, 15, pp.142~149 (2013)[DOI]
41. von Baum H, "Moxifloxacin prophylaxis in neutropenic patients", J Antimicrob Chemother, 58, pp.891~894 (2006)[DOI]
42. Mikulska M, "Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines", J Infect, 76, pp.20~37 (2018)[DOI]
43. Gea-Banacloche J, "Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies", Hematology Am Soc Hematol Educ Program, 2013, pp.414~422 (2013)
44. Averbuch D, "European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia", Haematologica, 98, pp.1826~1835 (2013)[DOI]
45. Kurosawa M, "Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies", Int J Hematol, 96, pp.748~757 (2012)[DOI]
46. Pagano L, "Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne", Clin Infect Dis, 45, pp.1161~1170 (2007)[DOI]
47. Choi JK, "Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of "RISK" Study", Biol Blood Marrow Transplant, 23, pp.1773~1779 (2017)[DOI]
48. [URL]
49. Leventakos K, "Fungal infections in leukemia patients: how do we prevent and treat them?", Clin Infect Dis, 50, pp.405~415 (2010)[DOI]
50. Kullberg BJ, "Invasive candidiasis", N Engl J Med, 373, pp.1445~1456 (2015)[DOI]
51. Pappas PG, "clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America", Clin Infect Dis, 62, pp.e1~e50 (2016)[DOI]
52. Wingard JR, "Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology", Infect Dis Clin North Am, 24, pp.257~272 (2010)[DOI]
53. Marchetti O, "ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients", Bone Marrow Transplant, 47, pp.846~854 (2012)[DOI]
54. Hsu LY, "Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study", Clin Microbiol Infect, 21, pp.594~ (2015)
55. Bergeron A, "The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies", Blood, 119, pp.1831~1837 (2012)[DOI]
56. 김시현, "Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population", Infection and Chemotherapy, 45(4), pp.406~414 (2013), 대한감염학회[DOI]
57. Maertens JA, "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial", Lancet, 387, pp.760~769 (2016)[DOI]
58. Tissot F, "ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients", Haematologica, 102, pp.433~444 (2017)[DOI]
59. Michallet M, "Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation", J Clin Oncol, 27, pp.3398~3409 (2009)[DOI]
60. Maertens J, "European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3. 2009 update", Bone Marrow Transplant, 46, pp.709~718 (2011)[DOI]
61. Kim SB, "Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: a 5-year retrospective cohort study", Med Mycol, 55, pp.237~245 (2017)
62. 박세윤, "Voriconazole-refractory invasive aspergillosis", The Korean Journal of Internal Medicine, 32(5), pp.805~812 (2017), 대한내과학회[DOI]
63. Cho SY, "Characteristics of culture- positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species", Medicine (Baltimore), 96, pp.e8841~ (2017)[DOI]
64. Maertens J, "ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients", J Antimicrob Chemother, 71, pp.2397~2404 (2016)[DOI]
65. 이혜연, "Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice", The Korean Journal of Internal Medicine, 32(3), pp.478~485 (2017), 대한내과학회[DOI]
66. Fan LC, "Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review", PLoS One, 8, pp.e73099~ (2013)[DOI]
67. Lu Y, "PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis", J Clin Microbiol, 49, pp.4361~4363 (2011)[DOI]
68. Alanio A, "ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients", J Antimicrob Chemother, 71, pp.2386~2396 (2016)[DOI]
69. Green H, "Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta- analysis of randomized controlled trials", Mayo Clin Proc, 82, pp.1052~1059 (2007)[DOI]
70. Green H, "Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients", Cochrane Database Syst Rev, (3) (2007)
71. Cordonnier C, "Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients", J Antimicrob Chemother, 71, pp.2379~2385 (2016)[DOI]
72. Cooley L, "Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014", Intern Med J, 44, pp.1350~1363 (2014)[DOI]
73. Thursky KA, "Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab", Br J Haematol, 132, pp.3~12 (2006)[DOI]
74. Boeckh M, "Cytomegalovirus: pathogen, paradigm, and puzzle", J Clin Invest, 121, pp.1673~1680 (2011)[DOI]
75. Ljungman P, "Definitions of cytomegalovirus infection and disease in transplant recipients", Clin Infect Dis, 34, pp.1094~1097 (2002)[DOI]
76. Ljungman P, "Management of CMV infections: recommendations from the infectious diseases working party of the EBMT", Bone Marrow Transplant, 33, pp.1075~1081 (2004)[DOI]
77. 최수미, "조혈모세포이식 환자에서 발생한 Cytomegalovirus 질환의 특징 : 일개 대학병원에서 최근 10년간의 경험", Infection and Chemotherapy, 41(1), pp.9~19 (2009), 대한감염학회
78. Jeon S, "Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation", Ophthalmology, 119, pp.1892~1898 (2012)[DOI]
79. Teira P, "Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis", Blood, 127, pp.2427~2438 (2016)[DOI]
80. Tark Kim, "Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy", The Korean Journal of Internal Medicine, 31(5), pp.961~970 (2016), 대한내과학회[DOI]
81. Lee HY, "Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies", Oncotarget, 8, pp.39736~39745 (2017)
82. 최수미, "Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant Recipients", Journal of Korean Medical Science, 24(4), pp.571~578 (2009), 대한의학회
83. Choi SM, "Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea", Int J Hematol, 81, pp.69~74 (2005)[DOI]
84. Cho BS, "Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy", Ann Hematol, 92, pp.497~504 (2013)[DOI]
85. Marty FM, "Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation", N Engl J Med, 377, pp.2433~2444 (2017)[DOI]
86. Khanna R, "Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management", J Clin Microbiol (2018)[DOI]
87. Yong MK, "Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation", J Infect Dis, 215, pp.1684~1694 (2017)[DOI]
88. Jung J, "Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients", J Clin Virol, 87, pp.5~11 (2017)[DOI]
89. 김성한, "Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation: a pilot proof-of-concept study", The Korean Journal of Internal Medicine, 32(5), pp.900~909 (2017), 대한내과학회[DOI]
90. 김성한, "Diagnostic Usefulness of Cytomegalovirus (CMV)- Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of- Concept Study", Infection and Chemotherapy, 47(2), pp.105~110 (2015), 대한감염학회[DOI]
91. Lee H, "Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON- CMV assay in seropositive kidney transplant recipients", PLoS One, 12, pp.e0189488~ (2017)[DOI]
92. 한상훈, "Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies", Infection and Chemotherapy, 49(3), pp.161~175 (2017), 대한감염학회
93. Park SH, "Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin", Transpl Infect Dis, 11, pp.413~423 (2009)[DOI]
94. Gilbert C, "Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients", Antimicrob Agents Chemother, 45, pp.3669~3671 (2001)[DOI]
95. Hantz S, "Drug-resistant cytomegalovirus in transplant recipients: a French cohort study", J Antimicrob Chemother, 65, pp.2628~2640 (2010)[DOI]
96. Shmueli E, "High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation", J Infect Dis, 209, pp.557~561 (2014)[DOI]
97. El Chaer F, "How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients", Blood, 128, pp.2624~2636 (2016)[DOI]
98. Kang CI, "Incidence of herpes zoster and seroprevalence of varicella- zoster virus in young adults of South Korea", Int J Infect Dis, 12, pp.245~247 (2008)[DOI]
99. Yun Hwa Kim, "Seroepidemiologic Survey of Varicella-Zoster Virus in Korean Adults Using Glycoprotein Enzyme Immuno Assay and Fluorescent Antibody to Membrane Antigen Test", Annals of Dermatology, 23(1), pp.39~43 (2011), 대한피부과학회
100. Choi WS, "Seroprevalence of varicella- zoster virus in Korea", J Med Virol, 82, pp.2123~2126 (2010)[DOI]
101. Styczynski J, "Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia", Bone Marrow Transplant, 43, pp.757~770 (2009)[DOI]
102. Kim DH, "Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation", Clin Transplant, 22, pp.770~779 (2008)[DOI]
103. Seo HM, "Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis", Antiviral Res, 140, pp.106~115 (2017)[DOI]
104. 박선희, "Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea", Journal of Korean Medical Science, 21(2), pp.259~264 (2006), 대한의학회
105. Styczynski J, "Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines", Haematologica, 101, pp.803~811 (2016)[DOI]
106. Kim YJ, "Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation", Leukemia, 16, pp.958~959 (2002)[DOI]
107. Dropulic LK, "Polyomavirus BK infection in blood and marrow transplant recipients", Bone Marrow Transplant, 41, pp.11~18 (2008)[DOI]
108. Ison MG, "Adenovirus infections in transplant recipients", Clin Infect Dis, 43, pp.331~339 (2006)[DOI]
109. Knowles WA, "Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40", J Med Virol, 71, pp.115~123 (2003)[DOI]
110. Kean JM, "Seroepidemiology of human polyomaviruses", PLoS Pathog, 5, pp.e1000363~ (2009)[DOI]
111. Egli A, "Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors", J Infect Dis, 199, pp.837~846 (2009)[DOI]
112. Rinaldo CH, "The human polyomavirus BK (BKPyV): virological background and clinical implications", APMIS, 121, pp.728~745 (2013)[DOI]
113. Cesaro S, "ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients", J Antimicrob Chemother, 73, pp.12~21 (2018)[DOI]
114. Erard V, "BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients", Blood, 106, pp.1130~1132 (2005)[DOI]
115. Cesaro S, "A prospective study on the predictive value of plasma BK virus-DNA load for hemorrhagic cystitis in pediatric patients after stem cell transplantation", J Pediatric Infect Dis Soc, 4, pp.134~142 (2015)[DOI]
116. Gaziev J, "Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir", Biol Blood Marrow Transplant, 16, pp.662~671 (2010)[DOI]
117. Koskenvuo M, "BK polyomavirus-associated hemorrhagic cystitis among pediatric allogeneic bone marrow transplant recipients: treatment response and evidence for nosocomial transmission", J Clin Virol, 56, pp.77~81 (2013)[DOI]
118. Kwon HJ, "Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience", Transpl Infect Dis, 15, pp.569~574 (2013)[DOI]
119. Faraci M, "Low dosage cidofovir without probenecid as treatment for BK virus hamorrhagic cystitis after hemopoietic stem cell transplant", Pediatr Infect Dis J, 28, pp.55~57 (2009)[DOI]
120. Ganguly N, "Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach", Transpl Infect Dis, 12, pp.406~411 (2010)[DOI]
121. 이승신, "Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation", The Korean Journal of Internal Medicine, 30(2), pp.212~218 (2015), 대한내과학회[DOI]
122. Savona MR, "Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant", Bone Marrow Transplant, 39, pp.783~787 (2007)[DOI]
123. Tylden GD, "Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells", Antimicrob Agents Chemother, 59, pp.3306~3316 (2015)[DOI]
124. Weigt SS, "Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients", Semin Respir Crit Care Med, 32, pp.471~493 (2011)[DOI]
125. Kumar D, "Respiratory viral infections in transplant and oncology patients", Infect Dis Clin North Am, 24, pp.395~412 (2010)[DOI]
126. 안미영, "Utilization of the respiratory virus multiplex reverse transcription-polymerase chain reaction test for adult patients at a Korean tertiary care center", The Korean Journal of Internal Medicine, 30(1), pp.96~103 (2015), 대한내과학회[DOI]
127. 홍경욱, "Lower Respiratory Tract Diseases Caused by Common Respiratory Viruses among Stem Cell Transplantation Recipients: A Single Center Experience in Korea", Yonsei Medical Journal, 58(2), pp.362~369 (2017), 연세대학교의과대학[DOI]
128. Shah JN, "Management of RSV infections in adult recipients of hematopoietic stem cell transplantation", Blood, 117, pp.2755~2763 (2011)[DOI]
129. Hirsch HH, "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus", Clin Infect Dis, 56, pp.258~266 (2013)[DOI]
130. Chemaly RF, "The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation", Blood, 119, pp.2738~2745 (2012)[DOI]
131. Nichols WG, "Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome", Blood, 98, pp.573~578 (2001)[DOI]
132. Ljungman P, "Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients", Haematologica, 96, pp.1231~1235 (2011)[DOI]
133. Schnell D, "Risk factors for pneumonia in immunocompromised patients with influenza", Respir Med, 104, pp.1050~1056 (2010)[DOI]
134. Engelhard D, "European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN", Transpl Infect Dis, 15, pp.219~232 (2013)[DOI]
135. Parody R, "Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies", Am J Hematol, 82, pp.807~811 (2007)[DOI]
136. Gutman JA, "Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases", Bone Marrow Transplant, 40, pp.809~811 (2007)[DOI]
137. Dignan FL, "BCSH", BSBMT, Br J Haematol, pp.2016, 173[DOI]
138. 백지현, "Guideline on the prevention and control of seasonal influenza in healthcare setting", The Korean Journal of Internal Medicine, 29(2), pp.265~280 (2014), 대한내과학회[DOI]
139. 최원석, "계절 인플루엔자의 항바이러스제 사용 지침", Infection and Chemotherapy, 44(4), pp.233~249 (2012), 대한감염학회
140. von Lilienfeld-Toal M, "Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology", Eur J Cancer, 67, pp.200~212 (2016)[DOI]
141. Shah DP, "Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections", Blood, 123, pp.3263~3268 (2014)[DOI]
142. de Fontbrune FS, "Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation", Clin Infect Dis, 45, pp.1019~1024 (2007)[DOI]
143. DeVincenzo JP, "Oral GS- 5806 activity in a respiratory syncytial virus challenge study", N Engl J Med, 371, pp.711~722 (2014)[DOI]
144. 최원석, "Severe influenza treatment guideline", The Korean Journal of Internal Medicine, 29(1), pp.132~147 (2014), 대한내과학회[DOI]
145. Bumbacea D, "The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement", Eur Respir J, 40, pp.990~1013 (2012)[DOI]
146. Lee HJ, "The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population", PLoS One, 12, pp.e0173250~ (2017)[DOI]
147. Fan WC, "Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study", Int J Tuberc Lung Dis, 19, pp.58~64 (2015)[DOI]
148. Al-Anazi KA, "Infections caused by mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation", Front Oncol, 4, pp.231~ (2014)
149. Lee J, "Tuberculosis in hematopoietic stem cell transplant recipients in Korea", Int J Hematol, 79, pp.185~188 (2004)[DOI]
150. Tsigrelis C, "Vaccinations in patients with hematological malignancies", Blood Rev, 30, pp.139~147 (2016)[DOI]
151. Chong PP, "A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients", Clin Ther, 39, pp.1581~1598 (2017)[DOI]
152. 이동건, "Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea", Infection and Chemotherapy, 45(3), pp.272~282 (2013), 대한감염학회

관련 논문AI추천